The von Hippel-Lindau tumor suppressor protein: Roles in cancer and oxygen sensing

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 70, Issue , 2005, Pages 159-166

  Kaelin Jr , W G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; GENE PRODUCT; HETERODIMER; LIGASE; NERVE GROWTH FACTOR; PROTEIN C JUN; TRANSCRIPTION FACTOR; VON HIPPEL LINDAU PROTEIN; DNA 26S; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR; OXYGEN; PROTEIN TYROSINE KINASE A; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE E3; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CANCER; CANCER INHIBITION; CELL METABOLISM; CONFERENCE PAPER; DOWN REGULATION; EXTRACELLULAR MATRIX; GENE ACTIVATION; GENE ISOLATION; GENE MUTATION; HEMANGIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MITOGENESIS; NONHUMAN; OXYGEN SENSING; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; UPREGULATION; ARTICLE; CARCINOGENESIS; DEREGULATION; GENE LOSS; GENE PRODUCT; HYDROXYLATION; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; MALIGNANT NEOPLASM; PARAGANGLIOMA; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE; XENOGRAFT;

ADRENAL GLAND NEOPLASMS; ANIMALS; DISEASE MODELS, ANIMAL; GENES, TUMOR SUPPRESSOR; HEMANGIOBLASTOMA; HIPPEL-LINDAU DISEASE; HUMANS; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; OXYGEN; PHEOCHROMOCYTOMA; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33746427905     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2005.70.001     Document Type: Conference Paper

References (116)

1. Adryan B., Decker H.-J.H., Papas T.S., and Hsu T. 2000. Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila. Oncogene 19: 2803.
2. Aiello L.P., George D.J., Cahill M.T., Wong J.S., Cavallerano J., Hannah A.L., and Kaelin W.G., Jr. 2002. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 109: 1745.
3. Aprelikova O., Chandramouli G.V., Wood M., Vasselli J.R., Riss J., Maranchie J.K., Linehan W.M., and Barrett J.C. 2004. Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J. Cell. Biochem. 92: 491.
4. Benjamin L.E., Golijanin D., Itin A., Pode D., and Keshet E. 1999. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103: 159.
5. Bergers G., Song S., Meyer-Morse N., Bergsland E., and Hanahan D. 2003. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111: 1287.
6. Berra E., Benizri E., Ginouves A., Volmat V., Roux D., and Pouyssegur J. 2003. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J. 22: 4082.
7. Bishop T., Lau K.W., Epstein A.C., Kim S.K., Jiang M., O'Rourke D., Pugh C.W., Gleadle J.M., Taylor M.S., Hodgkin J., and Ratcliffe P.J. 2004. Genetic analysis of pathways regulated by the von Hippel-Lindau tumor suppressor in Caenorhabditis elegans. PLoS Biol. 2: e289.
8. Blankenship C., Naglich J., Whaley J., Seizinger B., and Kley N. 1999. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene 18: 1529.
9. Bruick R. and McKnight S. 2001. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337.
10. Brunelle J.K., Bell E.L., Quesada N.M., Vercauteren K., Tiranti V., Zeviani M., Scarpulla R.C., and Chandel N.S. 2005. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab. 1: 409.
11. Chan C., Vortmeyer A., Chew E., Green W., Matteson D., Shen D., Linehan W., Lubensky I., and Zhuang Z. 1999. VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. Arch. Ophthalmol. 117: 625.
12. Chen F., Kishida T., Yao M., Hustad T., Glavac D., Dean M., Gnarra J.R., Orcutt M.L., Duh F.M., Glenn G., Green J., Hsia Y.E., Lamiell J., Ming H.W., Schmidt L., Kalman T., Kuzmin I., Stackhouse T., Latif F., Linehan W.M., Lerman M., and Zbar B. 1995. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Hum. Mutat. 5: 66.
13. Cioffi C.L., Liu X.Q., Kosinski P.A., and Bowen B.R. 2003. Differential regulation of HIF-1 alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells. Biochem. Biophys. Res. Commun. 303: 947.
14. Clifford S., Cockman M., Smallwood A., Mole D., Woodward E., Maxwell P., Ratcliffe P., and Maher E. 2001. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 10: 1029.
15. Cockman M., Masson N., Mole D., Jaakkola P., Chang G., Clifford S., Maher E., Pugh C., Ratcliffe P., and Maxwell P. 2000. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275: 25733.
16. Corless C.L., Kibel A., Iliopoulos O., and Kaelin W.G., Jr. 1997. Immunostaining of the von Hippel-Lindau gene product (pVHL) in normal and neoplastic human tissues. Hum. Pathol. 28: 459.
17. Czyzyk-Krzeska M.F. and Meller J. 2004. von Hippel-Lindau tumor suppressor: Not only HIF's executioner. Trends Mol. Med. 10: 146.
18. Davidowitz E., Schoenfeld A., and Burk R. 2001. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol. Cell. Biol. 21: 865.
19. Deckwerth T.L. and Johnson E.M., Jr. 1993. Temporal analysis of events associated with programmed cell death (apoptosis) of sympathetic neurons deprived of nerve growth factor. J. Cell Biol. 123: 1207.
20. del Peso L., Castellanos M.C., Temes E., Martin-Puig S., Cuevas Y., Olmos G., and Landazuri M.O. 2003. The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J. Biol. Chem. 278: 48690.
21. Duan D.R., Humphrey J.S., Chen D.Y.T., Weng Y., Sukegawa J., Lee S., Gnarra J.R., Linehan W.M., and Klausner R.D. 1995a. Characterization of the VHL tumor suppressor gene product: Localization, complex formation, and the effect of natural inactivating mutations. Proc. Natl. Acad. Sci. 92: 6495.
22. Duan D.R., Pause A., Burgress W., Aso T., Chen D.Y.T., Garrett K.P., Conaway R.C., Conaway J.W., Linehan W.M., and R.D. Klausner R.D. 1995b. Inhibition of transcriptional elongation by the VHL tumor suppressor protein. Science 269: 1402.
23. Edwards S.N. and Tolkovsky A.M. 1994. Characterization of apoptosis in cultured rat sympathetic neurons after nerve growth factor withdrawal. J. Cell Biol. 124: 537.
24. Epstein A., Gleadle J., McNeill L., Hewitson K., O'Rourke J., Mole D., Mukherji M., Metzen E., Wilson M., Dhanda A., Tian Y., Masson N., Hamilton D., Jaakkola P., Barstead R., Hodgkin J., Maxwell P., Pugh C., Schofield C., and Ratcliffe P. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43.
25. Esteban-Barragan M., Avila P., Alvarez-Tejado M., Gutierrez M., Garcia-Pardo A., Sanchez-Madrid F., and Landazuri M. 2002. Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions. Cancer Res. 62: 2929.
26. Estus S., Zaks W.J., Freeman R.S., Gruda M., Bravo R., and Johnson, E.M., Jr. 1994. Altered gene expression in neurons during programmed cell death: Identification of c-jun as necessary for neuronal apoptosis. J. Cell Biol. 127: 1717.
27. Flamme I., Krieg M., and Plate K. 1998. Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha. Am. J. Pathol. 153: 25.
28. Gao J., Naglich J.G., Laidlaw J., Whaley J.M., Seizinger B.R., and Kley N. 1995. Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: Implications for the potential organization of the human von Hippel-Lindau disease gene. Cancer Res. 55: 743.
29. Gerald D., Berra E., Frapart Y.M., Chan D.A., Giaccia A.J., Mansuy D., Pouyssegur J., Yaniv M., and Mechta-Grigoriou F. 2004. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118: 781.
30. Girmens J.F., Erginay A., Massin P., Scigalla P., Gaudric A., and Richard S. 2003. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am. J. Ophthalmol. 136: 194.
31. Gnarra J.R., Zhou S., Merrill M.J., Wagner J., Krumm A., Papavassiliou E., Oldfield E.H., Klausner R.D., and Linehan W.M. 1996. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumor suppressor gene product. Proc. Natl. Acad. Sci. 93: 10589.
32. Gnarra J., Ward J., Porter F., Wagner J., Devor D., Grinberg A., Emmert-Buck M., Westphal H., Klausner R., and Linehan W. 1997. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl. Acad. Sci. 94: 9102.
33. Groulx I. and Lee S. 2002. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 22: 5319.
34. Guzy R.D., Hoyos B., Robin E., Chen H., Liu L., Mansfield K.D., Simon M.C., Hammerling U., and Schumacker P.T. 2005. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab. 1: 401.
35. Haase V., Glickman J., Socolovsky M., and Jaenisch R. 2001. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl. Acad. Sci. 98: 1583.
36. Ham J., Babij C., Whitfield J., Pfarr C.M., Lallemand D., Yaniv M., and Rubin L.L. 1995. A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 14: 927.
37. Hirsila M., Koivunen P., Gunzler V., Kivirikko K.I., and Myllyharju J. 2003. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J. Biol. Chem. 278: 30772.
38. Hoffman M., Ohh M., Yang H., Klco J., Ivan M., and Kaelin W.G., Jr. 2001. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10: 1019.
39. Hon W.C., Wilson M.I., Harlos K., Claridge T.D., Schofield C.J., Pugh C.W., Maxwell P.H., Ratcliffe P.J., Stuart D.I., and Jones E.Y. 2002. Structural basis for the recognition of hydroxyproline in HIF-1alpha by pVHL. Nature 417: 975.
40. Iliopoulos O., Ohh M., and Kaelin W. 1998. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc. Natl. Acad. Sci. 95: 11661.
41. Iliopoulos O., Kibel A., Gray S., and Kaelin W.G. 1995. Tumor suppression by the human von Hippel-Lindau gene product. Nat. Med. 1: 822.
42. Iliopoulos O., Jiang C., Levy A.P., Kaelin W.G., and Goldberg M.A. 1996. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. 93: 10595.
43. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J., Lane W., and Kaelin W.G., Jr. 2001. HIFα targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292: 464.
44. Ivan M., Haberberger T., Gervasi D.C., Michelson K.S., Gunzler V., Kondo K., Yang H., Sorokina I., Conaway R.C., Conaway J.W., and Kaelin W.G., Jr. 2002. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc. Natl. Acad. Sci. 99: 13459.
45. Jaakkola P., Mole D., Tian Y., Wilson M., Gielbert J., Gaskell S., Kriegsheim A., Hebestreit H., Mukherji M., Schofield C., Maxwell P., Pugh C., and Ratcliffe P. 2001. Targeting of HIFalpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468.
46. Jiang Y., Zhang W., Kondo K., Klco J.M., St. Martin T.B., Dufault M.R., Madden S.L., Kaelin W.G., Jr., and Nacht M. 2003. Gene expression profiling in a renal cell carcinoma cell line: Dissecting VHL and hypoxia-dependent pathways. Mol. Cancer Res. 1: 453.
47. Kaelin W.G., Jr. 2002. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2: 673.
48. _. 2004. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin. Cancer Res. 10: 6290S.
49. Kamura T., Sato S., Iwain K., Czyzyk-Krzeska M., Conaway R.C., and Conaway J.W. 2000. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau tumor suppressor complex. Proc. Natl. Acad. Sci. 97: 10430.
50. Kamura T., Koepp D.M., Conrad M.N., Skowyra D., Moreland R.J., Iliopoulos O., Lane W.S., Kaelin W.G., Jr., Elledge S.J., Conaway R.C., Harper J.W., and Conaway J.W. 1999. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284: 657.
51. Kessler P., Vasavada S., Rackley R., Stackhouse T., Duh F., Latif F., Lerman M., Zbar B., and Williams B. 1995. Expression of the von Hippel-Lindau tumor-suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Mol. Med. 1: 457.
52. Kibel A., Iliopoulos O., DeCaprio J.D., and Kaelin W.G. 1995. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269: 1444.
53. Kieser A., Seitz T., Adler H.S., Coffer P., Kremmer E., Crespo P., Gutkind J.S., Henderson D.W., Mushinski J.F., Kolch W., and Mischak H. 1996. Protein kinase C-zeta reverts v-raf transformation of NIH-3T3 cells. Genes Dev. 10: 1455.
54. Kim W.Y. and Kaelin W.G. 2004. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22: 4991.
55. Kishida T., Stackhouse T.M., Chen F., Lerman M.I., and Zbar B. 1995. Cellular proteins that bind the von Hippel-Lindau disease gene product: Mapping of binding domains and the effect of missense mutations. Cancer Res. 55: 4544.
56. Kondo K., Kim W.Y., Lechpammer M., and Kaelin W.G., Jr. 2003. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1: E83.
57. Kondo K., Klco J., Nakamura E., Lechpammer M., and Kaelin W.G. 2002. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237.
58. Koochekpour S., Jeffers M., Wang P., Gong C., Taylor G., Roessler L., Stearman R., Vasselli J., Stetler-Stevenson W., Kaelin W.G., Jr., Linehan W., Klausner R., Gnarra J., and Vande Woude G. 1999. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol. Cell. Biol. 19: 5902.
59. Krieg M., Haas R., Brauch H., Acker T., Flamme I., and Plate K. 2000. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19: 5435.
60. Latif F., Tory K., Gnarra J., Yao M., Duh F.-M., Orcutt M.L., Stackhouse T., Kuzmin I., Modi W., Geil L., Schmidt L., Zhou F., Li H., Wei M.H., Chen F., Glenn G., Choyke P., Walther M.M., Weng Y., Duan D.-S.R., Dean M., Glavac D., Richards F.M., Crossey P.A., Ferguson-Smith M.A., Pasiler D.L., Chumakov I., Cohen D., Chinault A.C., Maher E.R., Linehan W.M., Zbar B., and Lerman M.I. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317.
61. Lee S., Chen D.Y.T., Humphrey J.S., Gnarra J.R., Linehan W.M., and Klausner R.D. 1996. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc. Natl. Acad. Sci. 93: 1770.
62. Lee S., Neumann M., Stearman R., Stauber R., Pause A., Pavlakis G., and Klausner R. 1999. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 19: 1486.
63. Lee S., Nakamura E., Yang H., Wei W., Linggi M., Sajan M., Farese R., Freeman R., Carter B., Kaelin W., and Schlisio S. 2005. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer. Cancer Cell (in press).
64. Lieubeau-Teillet B., Rak J., Jothy S., Iliopoulos O., Kaelin W., and Kerbel R. 1998. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res. 58: 4957.
65. Lipscomb E.A., Sarmiere P.D., and Freeman R.S. 2001. SM-20 is a novel mitochondrial protein that causes caspase-dependent cell death in nerve growth factor-dependent neurons. J. Biol. Chem. 276: 5085.
66. Lipscomb E., Sarmiere P., Crowder R., and Freeman R. 1999. Expression of the SM-20 gene promotes death in nerve growth factor-dependent sympathetic neurons. J. Neurochem. 73: 429.
67. Lonergan K.M., Iliopoulos O., Ohh M., Kamura T., Conaway R.C., Conaway J.W., and Kaelin W.G. 1998. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol. 18: 732.
68. Lubensky I.A., Gnarra J.R., Bertheau P., Walther M.M., Linehan W.M., and Zhuang Z. 1996. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am. J. Pathol. 149: 2089.
69. Ma W., Tessarollo L., Hong S.B., Baba M., Southon E., Back T.C., Spence S., Lobe C.G., Sharma N., Maher G.W., Pack S., Vortmeyer A.O., Guo C., Zbar B., and Schmidt L.S. 2003. Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res. 63: 5320.
70. Madhusudan S., Deplanque G., Braybrooke J.P., Cattell E., Taylor M., Price P., Tsaloumas M.D., Moore N., Huson S.M., Adams C., Frith P., Scigalla P., and Harris A.L. 2004. Antiangiogenic therapy for von Hippel-Lindau disease. J. Am. Med. Assoc. 291: 943.
71. Maher E.R. and Eng C. 2002. The pressure rises: Update on the genetics of phaeochromocytoma. Hum. Mol. Genet. 11: 2347.
72. Mandriota S.J., Turner K.J., Davies D.R., Murray P.G., Morgan N.V., Sowter H.M., Wykoff C.C., Maher E.R., Harris A.L., Ratcliffe P.J., and Maxwell P.H. 2002. HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1: 459.
73. Mansfield K.D., Guzy R.D., Pan Y., Young R.M., Cash T.P., Schumacher P.T., and Simon M.C. 2005. Loss of cytochrome C impairs cellular oxygen sensing and hypoxic HIF-α activation. Cell Metab. 1: 393.
74. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., and Klausner R.D. 2002. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1: 247.
75. Marxsen J.H., Stengel P., Doege K., Heikkinen P., Jokilehto T., Wagner T., Jelkmann W., Jaakkola P., and Metzen E. 2004. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-α-prolyl-4- hydroxylases. Biochem. J. 381: 761.
76. Masson N., Willam C., Maxwell P., Pugh C., and Ratcliffe P. 2001. Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation. EMBO J. 20: 5197.
77. Maxwell P., Weisner M., Chang G.-W., Clifford S., Vaux E., Pugh C., Maher E., and Ratcliffe P. 1999. The von Hippel-Lindau gene product is necessary for oxgyen-dependent proteolysis of hypoxia-inducible factor α subunits. Nature 399: 271.
78. Min J.H., Yang H., Ivan M., Gertler F., Kaelin W.G., Jr., and Pavletich N.P. 2002. Structure of an HIF-1α-pVHL complex: Hydroxyproline recognition in signaling. Science 296: 1886.
79. Nakayama K., Frew I.J., Hagensen M., Skals M., Habelhah H., Bhoumik A., Kadoya T., Erdjument-Bromage H., Tempst P., Frappell P.B., Bowtell D.D., and Ronai Z. 2004. Siah2 regulates stability of prolyl-hydroxylases, controls HIF1α abundance, and modulates physiological responses to hypoxia. Cell 117: 941.
80. Neumann H., Bausch B., McWhinney S., Bender B., Gimm O., Franke G., Schipper J., Klisch J., Altehoefer C., Zerres K., Januszewicz A., Smith W., Munk R., Manz T., Glaesker S., Apel T., Treier M., Reineke M., Walz M., Hoang-Vu C., Brauckhoff M., Klein-Franke A., Klose P., Schmidt H., Maier-Woelfle M., Peczkowska M., Szmigielski C., Eng C., and the Freiburg-Warsaw-Columbus Pheochromocytoma Study Group. 2002. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 343: 1459.
81. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.-Y., Huang L.E., Chau V., and Kaelin W.G. 2000. Ubiquitination of HIF requires direct binding to the von Hippel-Lindau protein beta domain. Nat. Cell Biol. 2: 423.
82. Ohh M., Takagi Y., Aso T., Stebbins C., Pavletich N., Zbar B., Conaway R., Conaway J., and Kaelin W.G., Jr. 1999. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J. Clin. Invest. 104: 1583.
83. Ohh M., Yauch R.L., Lonergan K.M., Whaley J.M., Stemmer-Rachamimov A.O., Louis D.N., Gavin B.J., Kley N., Kaelin W.G., Jr., and Iliopoulos O. 1998. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1: 959.
84. Okuda H., Saitoh K., Hirai S., Iwai K., Takaki Y., Baba M., Minato N., Ohno S., and Shuin T. 2001. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J. Biol. Chem. 276: 43611.
85. Okuda H., Hirai S., Takaki Y., Kamada M., Baba M., Sakai N., Kishida T., Kaneko S., Yao M., Ohno S., and Shuin T. 1999. Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem. Biophys. Res. Commun. 263: 491.
86. Pal S., Claffey K., Dvorak H., and Mukhopadhyay D. 1997. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J. Biol. Chem. 272: 27509.
87. Pause A., Lee S., Lonergan K.M., and Klausner R.D. 1998. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc. Natl. Acad. Sci. 95: 993.
88. Pause A., Peterson B., Schaffar G., Stearman R., and Klausner R. 1999. Studying interactions of four proteins in the yeast two-hybrid system: Structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc. Natl. Acad. Sci. 96: 9533.
89. Pause A., Lee S., Worrell R.A., Chen D.Y.T., Burgess W.H., Linehan W.M., and Klausner R.D. 1997. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. 94: 2156.
90. Rankin E.B., Higgins D.F., Walisser J.A., Johnson R.S., Bradfield C.A., and Haase V.H. 2005. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol. Cell. Biol. 25: 3163.
91. Reifenberger G., Reifenberger J., Bilzer T., Wechsler W., and Collins V. 1995. Coexpression of transforming growth factor-alpha and epidermal growth factor receptor in capillary hemangioblastomas of the central nervous system. Am. J. Pathol. 147: 245.
92. Renbaum P., Duh F.-M., Latif F., Zbar B., Lerman M., and Kuzmin I. 1996. Isolation and characterization of the full-length 3′ untranslated region of the human von Hippel-Lindau tumor suppressor gene. Hum. Genet. 98: 666.
93. Richard S., Campello C., Taillandier L., Parker F., and Resche F. 1998. Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. J. Int. Med. 243: 547.
94. Schlingensiepen K.H., Wollnik F., Kunst M., Schlingensiepen R., Herdegen T., and Brysch W. 1994. The role of Jun transcription factor expression and phosphorylation in neuronal differentiation, neuronal cell death, and plastic adaptations in vivo. Cell. Mol. Neurobiol. 14: 487.
95. Schoenfeld A., Davidowitz E., and Burk R. 1998. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl. Acad. Sci. 95: 8817.
96. _. 2001. Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region. Int. J. Cancer 91: 457.
97. Seizinger B.R., Rouleau G.A., Ozelius L.J., Lane A.H., Farmer G.E., Lamiell J.M., Haines J., Yuen J.W.M., Collins D., Majoor-Krakauer D., Bonner T., Mathew C., Rubenstein A., Halperin J., McConkie-Rosell A., Green J.S., Trofatter J.A., Ponder B.A., Eierman L., Bowmer M.I., Schimke R., Oostra B., Aronin N., Smith D.I., Drabkin H., Waziri M.H., Hobbs W.J., Martuza R.L., Conneally P.M., Hsia Y.E., and Gusella J.F. 1988. von-Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332: 268.
98. Selak M.A., Armour S.M., Mackenzie E.D., Boulahbel H., Watson D.G., Mansfield K.D., Pan Y., Simon M.C., Thompson C.B., and Gottlieb E. 2005. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7: 77.
99. Semenza G. 2000. HIF-1 and human disease: One highly involved factor. Genes Dev. 14: 1983.
100. Shiao Y.H., Resau J.H., Nagashima K., Anderson L.M., and Ramakrishna G. 2000. The von Hippel-Lindau tumor suppressor targets to mitochondria. Cancer Res. 60: 2816.
101. Siemeister G., Weindel K., Mohrs K., Barleon B., Martiny-Baron G., and Marme D. 1996. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56: 2299.
102. Simon M.C. 2004. Siah proteins, HIF prolyl hydroxylases, and the physiological response to hypoxia. Cell 117: 851-3.
103. Stebbins C.E., Kaelin W.G., Jr., and Pavletich N.P. 1999. Structure of the VHL-ElonginC-ElonginB complex: Implications for VHL tumor suppressor function. Science 284: 455.
104. Stolle C., Glenn G., Zbar B., Humphrey J., Choyke P., Walther M., Pack S., Hurley K., Andrey C., Klausner R., and Linehan W. 1998. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum. Mutat. 12: 417.
105. Stratmann R., Krieg M., Haas R., and Plate K. 1997. Putative control of angiogenesis in hemangioblastomas by the von Hippel-Lindau tumor suppressor gene. J. Neuropathol. Exp. Neurol. 56: 1242.
106. Straub J.A., Lipscomb E.A., Yoshida E.S., and Freeman R.S. 2003. Induction of SM-20 in PC12 cells leads to increased cytochrome c levels, accumulation of cytochrome c in the cytosol, and caspase-dependent cell death. J. Neurochem. 85: 318.
107. Tanimoto K., Makino Y., Pereira T., and Poellinger L. 2000. Mechanism of regulation of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19: 4298.
108. Vogel K.S., Brannan C.I., Jenkins N.A., Copeland N.G., and Parada L.F. 1995. Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic neurons. Cell 82: 733.
109. Vortmeyer A., Gnarra J., Emmert-Buck M., Katz D., Linehan W., Oldfield E., and Zhuang Z. 1997. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum. Pathol. 28: 540.
110. Wizigmann-Voos S., Breier G., Risau W., and Plate K. 1995. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res. 55: 1358.
111. Wykoff C., Pugh C., Maxwell P., Harris A., and Ratcliffe P. 2000. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19: 6297.
112. Ye Y., Vasavada S., Kuzmin I., Stackhouse T., Zbar B., and Williams B. 1998. Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Int. J. Cancer 78: 62.
113. Yu F., White S., Zhao Q., and Lee F. 2001. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. 98: 9630.
114. Zatyka M., da Silva N.F., Clifford S.C., Morris M.R., Wiesener M.S., Eckardt K.U., Houlston R.S., Richards F.M., Latif F., and Maher E.R. 2002. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res. 62: 3803.
115. Zhuang Z., Bertheau P., Emmert-Buck M., Liotta L., Gnarra J., Linehan W., and Lubensky I. 1995. A microscopic dissection technique for archival DNA analysis of specific cell populations in lesions <1mm in size. Am. J. Pathol. 146: 620.
116. Zimmer M., Doucette D., Siddiqui N., and Iliopoulos O. 2004. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol. Cancer Res. 2: 89.